Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer
Diabetic Medicine · 2024
DOI: 10.1111/dme.15292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2024. Verfasst von Julia C Harrod und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Diabetes Mellitus, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
In patients with breast cancer (BCa) and diabetes (DM), diabetes distress (DD) and treatment satisfaction (DTS) can influence BCa management and outcomes. We assessed the impact of implementing a personalized diabetes care model in patients with BCa.
Methods
Patients in active treatment or surveillance for BCa with an HbA1c > 53 mmol/mol (7%) or random blood glucose >11.1 mmol/L were included. Participants were offered continuous glucose monitoring (CGM), virtual care and a dedicated diabetes provider for 6 months. Primary outcomes included DD measured by the Diabetes Distress Survey (DDS) and DTS measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Questionnaires were conducted at 0, 3 and 6 months.
Results
Thirty‐one women were enrolled (median age 61, IQR 49.0–69.0). Compared to baseline, the mean DDS score was lower at both 3 months (2.2 vs. 1.8 [ n = 27], p = 0.004, SD = 0.70) and 6 months (2.3 vs. 1.8 [ n = 23], p = 0.002, SD = 0.70). The mean DTSQ score was higher at 3 months (baseline: 20.5 vs. 3 months: 28.7 [ n = 28], p < 0.001, SD = 9.2) and 6 months (baseline: 20.4 vs. 6 months: 30.0 [ n = 26], p < 0.001, SD = 9.7).
Conclusions
Personalized diabetes care models that emphasize remote management and optimize access for those with BCa may lower DD and improve DTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Division of Endocrinology, Diabetes and Metabolism, Northwell Health, Manhasset, New York, USA.
- Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
ORCID-Profile: Julia C Harrod
Förderung
- Eli Lilly and Company
Zitieren
APA
Harrod, J. C., Cheung, Y. M., Buckley, L., Cromwell, G. E., Fowler, K. M., Hughes, M. E., Lin, N. U., Tolaney, S. M., Min, L., & McDonnell, M. E. (2024). Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer. Diabetic Medicine. https://doi.org/10.1111/dme.15292
Vancouver
Harrod JC, Cheung YM, Buckley L, Cromwell GE, Fowler KM, Hughes ME, et al. Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer. Diabetic Medicine. 2024. doi:10.1111/dme.15292
BibTeX
@article{Harrod2024,
author = {Harrod, Julia C and Cheung, Yee-Ming M and Buckley, Lauren and Cromwell, Grace E and Fowler, Kristen M and Hughes, Melissa E and Lin, Nancy U and Tolaney, Sara M and Min, Le and McDonnell, Marie E},
title = {Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer},
journal = {Diabetic Medicine},
year = {2024},
doi = {10.1111/dme.15292}
}
EUVIMED